Madrigal Pharmaceuticals, X4 Pharmaceuticals and Day One Biopharmaceuticals secured their maiden approvals this year in metabolic dysfunction-associated steatohepatitis, WHIM syndrome and pediatric ...

Shares of Madrigal Pharmaceuticals, Inc. (NASDAQ:MDGL – Get Free Report) have been assigned a consensus recommendation of “Moderate Buy” from the thirteen ratings firms that are presently covering the ...

Smith covers the Healthcare sector, focusing on stocks such as Sagimet Biosciences, Inc. Class A, MoonLake Immunotherapeutics, and Madrigal Pharmaceuticals. Viking Therapeutics has an analyst ...

Madrigal Pharmaceuticals, Inc. (NASDAQ:MDGL), with a market capitalization of $6.66 billion, has positioned itself as a frontrunner in the treatment of nonalcoholic steatohepatitis (NASH ...

There’s a lot to be optimistic about in the Healthcare sector as 2 analysts just weighed in on Arcturus Therapeutics (ARCT – Research Report) ...

Look no further than our top two stories of the year, and you’ll see that the GLP-1 craze and Big Pharma layoffs took center ...

Madrigal Pharmaceuticals, Inc. (NASDAQ:MDGL), with a market capitalization of $6.66 billion, has positioned itself as a frontrunner in the treatment of nonalcoholic steatohepatitis (NASH) with its ...

Madrigal Pharmaceuticals, Inc. (NASDAQ:MDGL), a biopharmaceutical company focused on developing therapies for cardiovascular-metabolic diseases and nonalcoholic steatohepatitis (NASH), has ...

https://www.tipranks.com/news/the-fly/orthopediatrics-price-target-lowered-to-25-from-28-at-truist JMP Securities raised the firm’s price target on Madrigal ...

Madrigal Pharmaceuticals, Inc. (NASDAQ:MDGL), a biopharmaceutical company focused on developing therapies for cardiovascular-metabolic diseases and nonalcoholic steatohepatitis (NASH), has garnered ...

Detailed price information for Novo Nordisk A/S ADR (NVO-N) from The Globe and Mail including charting and trades.